XENETIC BIOSCIENCES INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
XENETIC BIOSCIENCES INC. - More news...
XENETIC BIOSCIENCES INC. - More news...
- Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
- Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
- Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
- Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
- Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
- Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
- Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
- Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
- Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
- Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
- Thinking about buying stock in Powerbridge Technologies, ExOne, Xenetic Biosciences, Opendoor Technologies, or Clover Health?
- Thinking about buying stock in Taoping, Xenetic Biosciences, Cocrystal Pharma, Nikola Corp, or SCWorx?
- Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
-
“The Buzz'' Show: Xenetic Biosciences Inc (NASDAQ: XBIO) USD 12.5 Million Private Stock Sale
- Thinking about buying stock in Xenetic Biosciences, Abeona Therapeutics, IMV Inc, Marathon Digital, or Riot Blockchain?
- Thinking about buying stock in Neurobo Pharmaceuticals, Xenetic Biosciences, Amneal Pharmaceuticals, PLx Pharma, or Orbital Energy Group?
-
“The Buzz” Show: Xenetic Biosciences (NASDAQ: XBIO) Rises on Positive Clinical Trial Data
-
Xenetic Biosciences, Inc. - XBIO Stock Chart Technical Analysis for 12-09-2020
-
Xenetic Biosciences, Inc. - XBIO Stock Chart Technical Analysis for 07-20-2020
